AGC Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASGLF research report →
Price Chart
About the company
AGC Inc. , a global enterprise headquartered in Tokyo, Japan, was established in 1907 and specializes in the production and distribution of a wide array of glass, electronics, chemicals, and ceramics products. The company's extensive glass offerings encompass architectural solutions like laminated, insulating, solar control, toughened, and decorative glass, in addition to structural glazing systems.
- CEO
- Yoshinori Hirai
- IPO
- 2009
- Employees
- 52,896
- HQ
- Tokyo, TY, JP
Get TickerSpark's AI analysis on ASGLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $8.15B
- P/E
- 15.14
- Fwd P/E
- 0.13
- PEG
- 0.70
- P/S
- 0.43
- P/B
- 0.65
- EV/EBITDA
- 4.67
- Div Yield
- 4.66%
- Gross Margin
- 23.45%
- Op Margin
- 5.39%
- Net Margin
- 2.86%
- ROE
- 4.22%
- ROIC
- 2.89%
Latest fiscal year · YoY change
- Revenue
- $2.06T-0.3%
- Gross Profit
- $500.88B+0.4%
- Op Income
- $125.58B
- Net Income
- $69.22B+173.6%
- EPS
- $326.49+173.6%
- OCF Growth
- -3.5%
- FCF Growth
- +53.1%
- 52W High
- $38.35
- 52W Low
- $30.40
- 50D MA
- $38.35
- 200D MA
- $36.66
- Beta
- 0.36
- RSI (14)
- 100
- Avg Volume
- 1.21K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
AGC posted higher sales in Q3 on yen weakness and stronger chemicals/electronics shipments, but profit was pressured by higher costs in automotive, chemicals and European glass, prompting a downward full-year outlook.· November 5, 2026
- Q3 sales rose to JPY 1,662.6 billion, but operating profit slipped to JPY 92.9 billion and net profit attributable to owners fell to JPY 33.4 billion.
- Chemicals was the standout: sales jumped to JPY 515.7 billion and operating profit surged to JPY 43.7 billion, helped by weaker yen and higher shipments/pricing.
- Automotive and Architectural Glass were weaker, with profit hit by higher manufacturing costs, European demand softness and repair/energy-related costs.
- Life Science losses narrowed year over year, but Q3 sales and profits were weak due to seasonality, Europe maintenance and delayed orders.
- Full-year guidance was cut: sales stay at JPY 2.2 trillion, but operating profit is lowered to JPY 120 billion and net profit to JPY 40 billion; the year-end dividend remains JPY 105 per share.
Third-quarter sales were JPY 1,662.6 billion, up JPY 150.5 billion year over year. Operating profit was JPY 92.9 billion, down JPY 1.9 billion; business profit was JPY 76.2 billion, down JPY 1.1 billion; profit before tax was JPY 70.4 billion, down JPY 2.8 billion; and profit attributable to owners of the parent was JPY 33.4 billion, down JPY 6.1 billion. For the first nine months, operating cash flow was JPY 150.1 billion, investing cash flow was negative JPY 120.8 billion, and free cash flow was positive JPY 29.3 billion. Full-year guidance was revised to sales of JPY 2.2 trillion, operating profit of JPY 120 billion, and net profit attributable to owners of JPY 40 billion; FX assumptions were changed to USD/JPY 160 and EUR/JPY 180. CapEx for the first three quarters was JPY 139.8 billion, and full-year CapEx is now expected to be JPY 205 billion. The company also reiterated a stable dividend policy targeting DOE of about 3%, with a planned year-end dividend of JPY 105 per share.
The CEO-level commentary emphasized that the downgrade reflected a mix of external pressure and internal execution issues, especially automotive manufacturing losses, weak essential chemicals spreads, and slower-than-expected recovery in Europe. Management said it needs a more conservative view on external assumptions and a stronger operating plan for next fiscal year. Tone-wise, the call was candid and self-critical, with management explicitly saying the company must not repeat the miss and must improve its internal structure and accountability.
Takegawa highlighted that higher raw material and fuel costs, weaker demand in European architectural glass, and higher manufacturing costs in automotive drove the profit decline despite stronger sales. He detailed segment results, including Architectural Glass sales of JPY 337.2 billion and operating profit of JPY 9.4 billion; Automotive sales of JPY 417.6 billion and operating profit of JPY 15.4 billion; Electronics sales of JPY 270.8 billion and operating profit of JPY 33.9 billion; Chemicals sales of JPY 515.7 billion and operating profit of JPY 43.7 billion; and Life Science operating loss of JPY 12.6 billion. He also gave balance-sheet and cash flow figures: total assets of JPY 2,943.1 billion, debt-to-equity of 0.40, operating cash flow of JPY 150.1 billion, and free cash flow of JPY 29.3 billion. CapEx was JPY 139.8 billion for the first nine months, with full-year CapEx now expected at JPY 205 billion.
Analysts pressed management on the reasons behind the full-year downgrade, especially one-time versus structural issues in automotive, essential chemicals, Europe gas costs, and Life Science delays. Management said automotive manufacturing problems in North America and Europe caused about JPY 15 billion of impact, that essential chemicals spreads remain volatile and not as favorable as expected, and that Europe’s gas-cost pass-through is delayed by several months. On Life Science, they said weak Q3 results were tied to Europe seasonality, maintenance, and delayed orders, but October and November are improving and the biopharma business may be near breakeven monthly. They also said display pricing increases are being pursued at a similar level to this year, and that next year they are confident they can improve on the current operating profit basis, despite the IFRS 18 reporting change.
Management still sees room for improvement in automotive, Life Science and chemicals next year, and said automotive losses should be more than offset over time. The strategic businesses grew strongly, with sales up to JPY 40.8 billion and operating profit up to JPY 57.6 billion, and management said these businesses made up 62% of group operating profit. They also pointed to recovering Life Science order intake, favorable demand in semiconductor-related materials, and continued pricing actions in display and chemicals.
The call showed that multiple businesses are still under pressure at the same time: automotive manufacturing inefficiencies, weak European architectural glass demand, volatile energy and feedstock costs, and slower-than-expected Life Science recovery. Management repeatedly said the Q4 and next-year timing is uncertain, with some issues taking until late this year or into the first half of next year to improve. The company also acknowledged that some misses were internal execution problems, not just market conditions, and that the full-year operating profit forecast had to be cut by JPY 30 billion.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 84.9%
- Shares Outstanding
- 212.39M
- Float Shares
- 180.39M
Our ASGLF coverage
Recent articles, reports, and earnings notes.
No research on ASGLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ASGLF report →